Xenon Pharmaceuticals (XENE) Other Gross PP&E Adjustments (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Other Gross PP&E Adjustments of -$6.3 million for Q1 2026, up 31.54% year-over-year from -$4.8 million in Q1 2025, and up 61.0% on a QoQ basis from -$16.1 million in Q4 2025.
Xenon Pharmaceuticals (XENE) has 14 years of Other Gross PP&E Adjustments data on file, last reported at -$6.3 million in Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 31.54% year-over-year to -$6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.3 million (up 31.54% YoY) and the FY2025 annual result came in at -$16.1 million, down 8.54% from the prior year.
- Other Gross PP&E Adjustments grew to -$6.3 million in Q1 2026 per XENE's latest filing, from -$16.1 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$3.0 million in Q4 2022 and bottomed at -$16.1 million in Q4 2025.
- The 5-year median for Other Gross PP&E Adjustments is -$9.8 million (2024), against an average of -$9.8 million.
- The widest annual swing landed in 2022, when Other Gross PP&E Adjustments plunged 1271.89%; it then jumped 31.54% in 2026.
- Tracing XENE's Other Gross PP&E Adjustments over 5 years: stood at -$3.0 million in 2022, then sank by 287.5% to -$11.5 million in 2023, then declined by 28.78% to -$14.9 million in 2024, then declined by 8.54% to -$16.1 million in 2025, then jumped by 61.0% to -$6.3 million in 2026.
- Per Business Quant, the three latest XENE Other Gross PP&E Adjustments figures stand at -$6.3 million (Q1 2026), -$16.1 million (Q4 2025), and -$9.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Xenon Pharmaceuticals | 4.78 Bn | 4.78 Bn | - | -6.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.29 Mn |
| Mar 31, 2026 | -6.29 Mn |
| Dec 31, 2025 | -16.12 Mn |
| Dec 31, 2025 | -16.12 Mn |
| Sep 30, 2025 | -9.48 Mn |
| Sep 30, 2025 | -9.48 Mn |
| Jun 30, 2025 | -8.03 Mn |
| Jun 30, 2025 | -8.03 Mn |
| Mar 31, 2025 | -9.19 Mn |
| Mar 31, 2025 | -9.19 Mn |
| Dec 31, 2024 | -14.86 Mn |
| Dec 31, 2024 | -14.86 Mn |
| Sep 30, 2024 | -9.82 Mn |
| Sep 30, 2024 | -9.82 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Mar 31, 2024 | -10.49 Mn |
| Mar 31, 2024 | -10.49 Mn |
| Dec 31, 2023 | -11.54 Mn |
| Dec 31, 2023 | -11.54 Mn |
| Sep 30, 2023 | -10.43 Mn |
| Sep 30, 2023 | -10.43 Mn |
| Jun 30, 2023 | -10.69 Mn |
| Jun 30, 2023 | -10.69 Mn |
| Mar 31, 2023 | -10.93 Mn |
| Mar 31, 2023 | -10.93 Mn |
| Dec 31, 2022 | -2.98 Mn |
| Dec 31, 2022 | -2.98 Mn |
| Sep 30, 2022 | -8.53 Mn |
| Sep 30, 2022 | -8.53 Mn |
| Jun 30, 2022 | -8.68 Mn |
| Jun 30, 2022 | -8.68 Mn |
| Mar 31, 2022 | -8.06 Mn |
| Mar 31, 2022 | -8.06 Mn |
| Dec 31, 2021 | -217,000.00 |
| Dec 31, 2021 | -217,000.00 |
| Sep 30, 2021 | -3.35 Mn |
| Sep 30, 2021 | -3.35 Mn |
| Jun 30, 2021 | -3.45 Mn |
| Jun 30, 2021 | -3.45 Mn |
| Mar 31, 2021 | -3.50 Mn |
| Mar 31, 2021 | -3.50 Mn |
| Dec 31, 2020 | 2.73 Mn |
| Dec 31, 2020 | 2.73 Mn |
| Sep 30, 2020 | -1.08 Mn |
| Sep 30, 2020 | -1.08 Mn |
| Jun 30, 2020 | -1.25 Mn |
| Jun 30, 2020 | -1.25 Mn |
| Mar 31, 2020 | -1.07 Mn |
| Mar 31, 2020 | -1.07 Mn |
| Dec 31, 2019 | 1.39 Mn |
| Dec 31, 2019 | 1.39 Mn |
| Sep 30, 2019 | -1.34 Mn |
| Sep 30, 2019 | -1.34 Mn |
| Jun 30, 2019 | -1.40 Mn |
| Jun 30, 2019 | -1.40 Mn |
| Mar 31, 2019 | -1.48 Mn |
| Mar 31, 2019 | -1.48 Mn |
| Dec 31, 2018 | 2.22 Mn |
| Dec 31, 2018 | 2.22 Mn |
| Sep 30, 2018 | -415,000.00 |
| Sep 30, 2018 | -415,000.00 |
| Jun 30, 2018 | -242,000.00 |
| Jun 30, 2018 | -242,000.00 |
| Mar 31, 2018 | -253,000.00 |
| Mar 31, 2018 | -253,000.00 |
| Dec 31, 2017 | 791,000.00 |
| Dec 31, 2017 | 791,000.00 |
| Sep 30, 2017 | -223,000.00 |
| Sep 30, 2017 | -223,000.00 |
| Jun 30, 2017 | -358,000.00 |
| Jun 30, 2017 | -358,000.00 |
| Mar 31, 2017 | -305,000.00 |
| Mar 31, 2017 | -305,000.00 |
| Dec 31, 2016 | 6.28 Mn |
| Dec 31, 2016 | 6.28 Mn |
| Sep 30, 2016 | -544,000.00 |
| Sep 30, 2016 | -544,000.00 |
| Jun 30, 2016 | -246,000.00 |
| Jun 30, 2016 | -246,000.00 |
| Mar 31, 2016 | -167,000.00 |
| Mar 31, 2016 | -167,000.00 |
| Dec 31, 2015 | 6.71 Mn |
| Dec 31, 2015 | 6.71 Mn |
| Sep 30, 2015 | -180,000.00 |
| Sep 30, 2015 | -180,000.00 |
| Jun 30, 2015 | -216,000.00 |
| Jun 30, 2015 | -216,000.00 |
| Mar 31, 2015 | -171,000.00 |
| Mar 31, 2015 | -171,000.00 |
| Dec 31, 2014 | 800,000.00 |
| Dec 31, 2014 | 800,000.00 |
| Sep 30, 2014 | -804,000.00 |
| Sep 30, 2014 | -804,000.00 |
| Dec 31, 2013 | 375,000.00 |
| Dec 31, 2013 | 375,000.00 |